西藏药业(600211) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was RMB 656,135,778.33, representing a year-on-year increase of 32.74%[5] - The net profit attributable to shareholders for Q1 2022 was RMB 174,668,206.63, reflecting an increase of 11.13% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 182,566,204.88, up by 27.68% year-on-year[5] - The basic earnings per share for Q1 2022 was RMB 0.70, marking an increase of 11.11% year-on-year[5] - The diluted earnings per share for Q1 2022 was also RMB 0.70, reflecting an increase of 11.11% compared to the same period last year[5] - The total operating revenue for Q1 2022 was CNY 656,135,778.33, an increase of 32.8% compared to CNY 494,293,289.21 in Q1 2021[28] - The net profit for Q1 2022 was CNY 176,249,968.12, compared to CNY 158,563,524.68 in Q1 2021, representing an increase of 11.0%[30] - Total comprehensive income amounted to CNY 171,724,467.56, an increase from CNY 169,334,500.48 year-over-year[32] - Basic and diluted earnings per share increased to CNY 0.70 from CNY 0.63 in the previous year[32] Cash Flow - The net cash flow from operating activities for Q1 2022 was RMB 242,413,333.94, which is an increase of 10.03% compared to the previous year[5] - Cash inflow from operating activities reached CNY 727,580,990.05, compared to CNY 540,272,824.77 in the first quarter of 2021, reflecting a significant growth[34] - Net cash flow from operating activities was CNY 242,413,333.94, up from CNY 220,317,632.56 year-over-year[34] - Cash inflow from investment activities totaled CNY 302,746,133.10, a substantial increase compared to CNY 707.96 in the previous year[34] - Net cash flow from investment activities was negative at CNY -98,061,380.28, improving from CNY -324,030,839.64 year-over-year[34] - Cash inflow from financing activities was CNY 35,999,521.37, down from CNY 40,079,075.99 in the previous year[34] - The net increase in cash and cash equivalents was CNY 172,226,199.18, contrasting with a decrease of CNY -63,355,434.79 in the previous year[34] - The ending balance of cash and cash equivalents was CNY 928,640,467.56, up from CNY 705,076,989.66 year-over-year[34] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to RMB 4,036,144,500.18, which is a 6.14% increase from the end of the previous year[5] - The total assets as of Q1 2022 were CNY 4,036,144,500.18, compared to CNY 3,802,655,776.83 at the end of the previous year, showing a growth of 6.1%[28] - The company reported an increase in accounts receivable to RMB 459,919,020.96 from RMB 471,373,735.72, indicating a decrease of approximately 2.43%[25] - The company’s total liabilities decreased from RMB 1,200,000,000 to RMB 1,150,000,000, showing a reduction of about 4.17%[25] - The total liabilities for Q1 2022 were CNY 1,219,399,709.29, an increase from CNY 1,157,635,453.49 in the previous year, reflecting a rise of 5.3%[28] - The company reported a decrease in accounts payable to CNY 82,490,089.62 from CNY 101,136,917.95, a decline of 18.5%[28] - The total equity attributable to shareholders increased to CNY 2,800,501,640.60 from CNY 2,630,358,934.53, reflecting a growth of 6.5%[28] Investments and R&D - The significant increase in operating revenue was primarily driven by a substantial rise in the sales of new products[10] - Research and development expenses in Q1 2022 were CNY 9,926,809.57, significantly higher than CNY 1,418,199.60 in Q1 2021, indicating a focus on innovation[30] - The company has secured exclusive sales rights for four in-development products in the Chinese market, including a fully biodegradable drug-eluting stent system and a high-pressure balloon dilation catheter[16] - The company has obtained a pharmaceutical production license for its new production base in Lhasa Economic and Technological Development Zone[16] Dividends - The company’s annual dividend plan was approved, distributing RMB 0.338 per share to all shareholders, based on a total share capital of 247,937,843 shares[16] Taxation - The company reported a tax expense of CNY 87,355,407.49, compared to CNY 53,035,392.45 in the previous year, indicating increased tax obligations[34]